Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from #x3e;104,000 procedures were documented, and TA was performed on #x3e;15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11% of patients. Patients with indications such as neurological diseases underwent plasma exchange (28%). Extracorporeal photochemotherapy, lipid apheresis, and antibody removal were other indications. Side effects recorded in the registry have decreased significantly over the years, with approximately only 10/10,000 procedures being interrupted for medical reasons. Conclusion: Collection of data from TA procedures within a multinational and multicenter concept facilitates the improvement of treatment by enabling the analysis of and feedback on indications, procedures, effects, and side effects.
Transfus Med Hemother

中文翻译：

---

使用世界单采协会登记有助于提高治疗性单采的治疗质量

治疗性单采术 (TA) 适用于患有严重进行性疾病且常规药物治疗不足的患者。获得更多关于这种治疗的知识的方法通常是对数据进行本地分析。然而，使用大型质量评估登记系统可以分析甚至罕见的发现。在这里，我们报告了来自世界单采协会 (WAA) 登记处的一些最新数据。记录了来自 #x3e;104,000 例程序的数据，并对 #x3e;15,000 名患者进行了 TA。TA 的主要适应症是收集自体干细胞（45% 的患者）作为治疗的一部分。11% 的患者从供体收集干细胞用于同种异体移植。有神经系统疾病等适应症的患者接受了血浆置换（28%）。体外光化学疗法、脂质单采和抗体去除是其他适应症。多年来，登记处记录的副作用显着减少，大约只有 10/10,000 例程序因医疗原因而中断。结论：在跨国和多中心概念内从 TA 程序收集数据有助于通过对适应症、程序、效果和副作用的分析和反馈来改进治疗。
Transfus Med Hemother